Editorial: Cell-based Therapies for Stroke: Promising Solution or Dead End?
作者信息
Boltze Johannes, Abe Koji, Clarkson Andrew N, Detante Oliver, Pimentel-Coelho Pedro M, Rosado-de-Castro Paulo H, Janowski Miroslaw
机构信息
School of Life Sciences, University of Warwick, Coventry, United Kingdom.
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
出版信息
Front Neurol. 2020 Apr 3;11:171. doi: 10.3389/fneur.2020.00171. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Cell-based Therapies for Stroke: Promising Solution or Dead End?社论：基于细胞的中风治疗方法：是充满希望的解决方案还是死胡同？
Front Neurol. 2020 Apr 3;11:171. doi: 10.3389/fneur.2020.00171. eCollection 2020.
2
Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research.中风的细胞疗法：是充满希望的解决方案还是死胡同？临床前中风研究中的间充质干细胞与合并症
Front Neurol. 2019 Apr 9;10:332. doi: 10.3389/fneur.2019.00332. eCollection 2019.
3
Essential Role of Chinese Medicines in Mesenchymal Stem Cells Transplantation for Treatment of Ischemic Stroke.中药在骨髓间充质干细胞移植治疗缺血性脑卒中中的重要作用。
Chin J Integr Med. 2019 Oct;25(10):723-727. doi: 10.1007/s11655-019-2708-4. Epub 2019 Nov 28.
4
Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression.细胞外囊泡可改善中风后的神经再生并预防缺血后免疫抑制。
Stem Cells Transl Med. 2015 Oct;4(10):1131-43. doi: 10.5966/sctm.2015-0078. Epub 2015 Sep 3.
5
Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet?精简综述：脑卒中患者的干细胞治疗：我们成功了吗？
Stem Cells Transl Med. 2019 Sep;8(9):983-988. doi: 10.1002/sctm.19-0076. Epub 2019 May 16.
6
Self-assembled GFFYK peptide hydrogel enhances the therapeutic efficacy of mesenchymal stem cells in a mouse hindlimb ischemia model.自组装 GFFYK 肽水凝胶增强间充质干细胞在小鼠后肢缺血模型中的治疗效果。
Acta Biomater. 2019 Feb;85:94-105. doi: 10.1016/j.actbio.2018.12.015. Epub 2018 Dec 11.
7
Interaction between hypothermia and delayed mesenchymal stem cell therapy in neonatal hypoxic-ischemic brain injury.低温与延迟间充质干细胞治疗在新生儿缺氧缺血性脑损伤中的相互作用。
Brain Behav Immun. 2018 May;70:118-130. doi: 10.1016/j.bbi.2018.02.006. Epub 2018 Feb 14.
8
Mesenchymal Stem Cell-Derived Extracellular Vesicle Therapy for Stroke: Challenges and Progress.间充质干细胞衍生的细胞外囊泡治疗中风：挑战与进展
Front Neurol. 2019 Mar 12;10:211. doi: 10.3389/fneur.2019.00211. eCollection 2019.
9
From bone to brain: human skeletal stem cell therapy for stroke.从骨骼到大脑：人类骨骼干细胞治疗中风
Cent Nerv Syst Agents Med Chem. 2011 Jun 1;11(2):157-63. doi: 10.2174/187152411796011376.
10
Fibroblast Growth Factor Type 1 (FGF1)-Overexpressed Adipose-Derived Mesenchaymal Stem Cells (AD-MSC) Induce Neuroprotection and Functional Recovery in a Rat Stroke Model.成纤维细胞生长因子 1 型（FGF1）过表达脂肪间充质干细胞（AD-MSC）在大鼠中风模型中诱导神经保护和功能恢复。
Stem Cell Rev Rep. 2017 Oct;13(5):670-685. doi: 10.1007/s12015-017-9755-z.
引用本文的文献
1
Dental-Pulp Stem Cells as a Therapeutic Strategy for Ischemic Stroke.牙髓干细胞作为缺血性中风的一种治疗策略
Biomedicines. 2022 Mar 22;10(4):737. doi: 10.3390/biomedicines10040737.
本文引用的文献
1
Statistical methods for biomarker data pooled from multiple nested case-control studies.从多个嵌套病例对照研究中汇集的生物标志物数据的统计方法。
Biostatistics. 2021 Jul 17;22(3):541-557. doi: 10.1093/biostatistics/kxz051.
2
Stem Cells as an Emerging Paradigm in Stroke 4: Advancing and Accelerating Preclinical Research.干细胞作为中风领域的新兴范例4：推进和加速临床前研究
Stroke. 2019 Nov;50(11):3299-3306. doi: 10.1161/STROKEAHA.119.025436. Epub 2019 Oct 17.
3
Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.静脉注射异体间充质干细胞治疗慢性脑卒中的安全性和初步疗效的 I/II 期研究。
Stroke. 2019 Oct;50(10):2835-2841. doi: 10.1161/STROKEAHA.119.026318. Epub 2019 Sep 9.
4
Neuronal Stem Cell and Drug Interactions: A Systematic Review and Meta-Analysis: Concise Review.神经干细胞与药物相互作用：系统评价和荟萃分析：简明综述。
Stem Cells Transl Med. 2019 Nov;8(11):1202-1211. doi: 10.1002/sctm.19-0020. Epub 2019 Jul 16.
5
Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy?缺血性中风的细胞治疗：临床前和临床研究设计的差异是否导致了疗效的转化损失？
Ann Neurol. 2019 Jul;86(1):5-16. doi: 10.1002/ana.25493. Epub 2019 May 8.
6
Machine Learning-Based Model for Prediction of Outcomes in Acute Stroke.基于机器学习的急性脑卒中结局预测模型。
Stroke. 2019 May;50(5):1263-1265. doi: 10.1161/STROKEAHA.118.024293.
7
A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke).一项自体骨髓源性 ALD-401 细胞经颈内动脉输注治疗近期稳定缺血性脑卒中患者的 2 期随机、假手术对照临床试验（RECOVER-Stroke）。
Circulation. 2019 Jan 8;139(2):192-205. doi: 10.1161/CIRCULATIONAHA.117.030659.
8
Intra-Arterial Delivery of Cell Therapies for Stroke.用于中风的细胞疗法的动脉内递送
Stroke. 2018 May;49(5):1075-1082. doi: 10.1161/STROKEAHA.117.018288. Epub 2018 Apr 18.
9
Integrin α4 Overexpression on Rat Mesenchymal Stem Cells Enhances Transmigration and Reduces Cerebral Embolism After Intracarotid Injection.整合素α4 在大鼠间充质干细胞中的过表达增强了经颈动脉内注射后的细胞穿越能力，并减少了脑栓塞。
Stroke. 2017 Oct;48(10):2895-2900. doi: 10.1161/STROKEAHA.117.017809. Epub 2017 Sep 15.
10
Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial.多能成体祖细胞治疗急性缺血性脑卒中的安全性和有效性研究（MASTERS）：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Neurol. 2017 May;16(5):360-368. doi: 10.1016/S1474-4422(17)30046-7. Epub 2017 Mar 17.
Zotero 插件